Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT ID: NCT02392676

Last Updated: 2016-05-02

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-31
• Study Completion Date: 2019-06-30

Brief Summary

Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected deleterious) somatic BRCA mutations or loss of function (deleterious or suspected deleterious) mutation in non-BRCA Homologous Recombination Repair (HRR) -associated genes who have a complete or partial response to platinum-based chemotherapy.

Detailed Description

This is a phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade epithelial ovarian cancer patients (including patients with primary peritoneal and / or fallopian tube cancer) who have responded following platinum based chemotherapy. The study population will be enrolled as two separate cohorts that will enrol simultaneously. The confirmatory cohort will consist of patients who carry a somatic BRCA mutation (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious) which are detected in tumour material but absent from germline blood testing ; the exploratory cohort will include patients with a mutation (documented mutation predicted to be deleterious or suspected deleterious) in non BRCA HRR-associated genes which are detected in tumour material regardless of their germline status.

Conditions

Platinum Sensitive Relapsed Ovarian Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

1/OLAPARIB

olaparib 300 mg oral tablets; twice daily

Group Type: EXPERIMENTAL

OLAPARIB

Intervention Type: DRUG

Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria

2/PLACEBO

placebo matching olaparib 300 mg oral tablets; twice daily

Group Type: PLACEBO_COMPARATOR

PLACEBO

Intervention Type: DRUG

Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria

Interventions

OLAPARIB

Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria

Intervention Type: DRUG

PLACEBO

Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients must be ≥ 18 years of age
• Histologically diagnosed relapsed high grade epithelial ovarian cancer (including primary peritoneal and/ or fallopian tube cancer)
• Documented deleterious or suspected deleterious somatic BRCA 1 and/or BRCA 2 somatic mutation or evidence of non- BRCA HRR-associated gene mutation in the tumour.
• At least 2 previous lines of platinum containing therapy prior to randomisation.
• CA-125 measurements prior to randomised treatment
• Patients must have normal organ and bone marrow function measured within 28 days of randomisation
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Postmenopausal or evidence of non-childbearing status for women of childbearing potential
• Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
• Provision of a blood sample for cfDNA biomarker analysis in Pre-Screening Part 1
• Formalin fixed, paraffin embedded (FFPE) tumour sample from the primary or recurrent cancer must be available for central testing. If archival tumour sample is not available tumour sample from fresh biopsy is acceptable, for all patients eligible to participate in Pre-Screening part 2.

Exclusion Criteria

• Documented germline mutation in BRCA1 and/or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function).
• Patients who have had drainage of their ascites from the final 2 cycles of their last chemotherapy regimen prior to randomisation on the study
• Participation in another clinical study with an investigational product during the chemotherapy course immediately prior to randomisation
• Any previous treatment with a PARP inhibitor, including olaparib
• Patients with a known hypersensitivity to olaparib or any of the excipients of the product
• Prior malignancy in the last 5 years, unless curatively treated and recurrence free (few exceptions apply)
• Patients receiving any systemic chemotherapy (including chemotherapy received as the most recent anticancer therapy) or radiotherapy (except for palliative reasons) within 3 weeks prior to study randomised treatment
• Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) CTCAE grade 2) caused by previous cancer therapy, excluding CTCAE grade 2 peripheral neuropathy
• Patients with myelodysplastic syndrome/acute myeloid leukaemia (t-AML) or with features suggestive of MDS/AML
• Patients with symptomatic uncontrolled brain metastases
• Major surgery within 2 weeks of starting study randomised treatment and patients must have recovered from any effects of any major surgery
• Patients considered a poor medical risk

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 96 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Myriad Genetic Laboratories, Inc.

INDUSTRY

Sponsor Role: collaborator

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Charlie Gourley, Prof.

Role: PRINCIPAL_INVESTIGATOR

University of Edinburgh

Carol Aghajanian, MD

Role: PRINCIPAL_INVESTIGATOR

MSKCC

Locations

Research Site

Mobile, Alabama, United States

Research Site

Phoenix, Arizona, United States

Research Site

Los Angeles, California, United States

Research Site

Stanford, California, United States

Research Site

Augusta, Georgia, United States

Research Site

Park Ridge, Illinois, United States

Research Site

Iowa City, Iowa, United States

Research Site

Louisville, Kentucky, United States

Research Site

Covington, Louisiana, United States

Research Site

Scarborough, Maine, United States

Research Site

Baltimore, Maryland, United States

Research Site

Albany, New York, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Milwaukee, Wisconsin, United States

Research Site

Chiclayo, , Peru

Research Site

Lima, , Peru

Research Site

Quezon City, , Philippines

Research Site

Goyang-si, , South Korea

Research Site

Seongnam-si, , South Korea

Research Site

Seoul, , South Korea

Research Site

Birmingham, , United Kingdom

Research Site

Cambridge, , United Kingdom

Research Site

Coventry, , United Kingdom

Research Site

Edinburgh, , United Kingdom

Research Site

London, , United Kingdom

Research Site

Manchester, , United Kingdom

Research Site

Oxford, , United Kingdom

Research Site

Sutton, , United Kingdom

Countries

United States; Peru; Philippines; South Korea; United Kingdom

Other Identifiers

D0816C00009

Identifier Type: -

Identifier Source: org_study_id